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CLINICAL OUTCOMES ASSOCIATED WITH TIME TO ANTIMICROBIAL 
THERAPY CHANGE FROM VANCOMYCIN TO DAPTOMYCIN IN 
STAPHYLOCOCCAL BACTEREMIA 
 
Background: Staphylococcus aureus is an aerobic, Gram positive commensal organism 
that is capable of causing a wide spectrum of disease. This study contributes to 
previously published literature regarding daptomycin versus vancomycin use in S. aureus 
bacteremia (SAB). 
 
Methods: Adult patients admitted between 2010 and 2014, billed for ICD-9 code V09.0, 
038.11, 038.12, 041.11, or 041.12, and received vancomycin and daptomycin were 
included in this retrospective analysis. Patients were stratified by time to change in 
antibiotics from vancomycin to daptomycin to the early switch (1-3 days), intermediate 
switch (4-7 days), or late switch (8 days or later) group. The primary outcome was 
treatment failure defined as 30-day recurrence, 60-day all-cause mortality, and 90-day 
all-cause readmission. 
 
Results: 193 patients were enrolled in the final cohort. The overall treatment failure rate 
was 18% with no differences between early switch, intermediate switch, and late switch 
(P=0.72) groups. Independent predictors of treatment success were length of stay 
(OR=1.035) and time to positive culture (OR=0.961). 
 
Conclusions: Results of this study did not demonstrate a difference in treatment failure 
based on time to switch from vancomycin to daptomycin. Future research should focus 
on optimizing use of vancomycin and daptomycin and medical management of SAB. 
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CHAPTER ONE: BACKGROUND 
 
Staphylococcus aureus is an aerobic, Gram positive bacterium naturally found as a 
commensal organism on the skin of humans. It especially resides in the nares and can be 
a facultative anaerobic organism.1 Once it breaches the barrier of the skin, S. aureus can 
become an opportunistic pathogen capable of causing a wide spectrum of disease in 
humans including skin and soft tissue infections (SSTIs), osteoarticular infections, 
pleuropulmonary disease, food poisoning and gastrointestinal upset, meningitis, and 
bloodstream infection (BSI) and infective endocarditis (IE).2,3 Surface adhesins on the 
bacteria mediate adherence to and colonization of end target tissues.1,2. Mobile genetic 
elements are responsible for development of antibiotic resistance mechanisms that have 
allowed S. aureus infections to persist during the antibiotic era. Key mobile genetic 
elements that will be discussed include bla genes which are responsible for beta-
lactamase production, and the staphylococcal cassette chromosome (SCC) which is 
responsible for methicillin resistance.2,4 
 
In 1940, penicillin became widely available and revolutionized management of infectious 
diseases. This prototypical beta-lactam has bactericidal activity by binding to penicillin-
binding protein in the cell wall of Gram-positive organisms and inhibiting peptidoglycan 
cross-linking, thus disrupting cell wall synthesis.5 By 1942, S. aureus demonstrated 
resistance to penicillin through production of a beta-lactamase enzyme that is capable of 
hydrolyzing the beta-lactam ring central to penicillin and inactivating the compound.2,6 
Now, more than 85% of S. aureus isolates produce this beta-lactamase.7 There are three 
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key bla genes that confer beta-lactamase production: blaZ, blaR, and blaI.2,4 They are 
encoded on transposons or plasmids and are inducible. Plasmids are auto-replicating 
DNA molecules that exist separate from the chromosome. blaR and blaI are regulator 
genes that also be found on the SCCmec that will be discussed in more detail.2 
 
In 1959, beta-lactam antibiotics that remained stable against this beta-lactamase were 
developed with methicillin being the prototypical agent in this antistaphylococcal class. 
In 1961, methicillin-resistant isolates of S. aureus began to emerge.8 Methicillin 
resistance is caused by alteration of the beta-lactam binding site at penicillin binding 
protein (PBP) 2a which has decreased affinity for beta-lactam antibiotics. This altered 
PBP is encoded by the mecA gene SCCmec.2,4 The SCC is a large fragment of DNA that 
is always inserted into the S. aureus chromosome. There are other SCC groups that do 
not confer methicillin resistance, so these are referred to as non-SCCmec groups. All 
methicillin-resistant S. aureus (MRSA) contain one type out of eight SCCmec types. 
These different types are responsible for community-acquired (CA-MRSA) versus 
hospital-acquired (HA-MRSA), which cause distinct infectious syndromes in different 
patient populations.4  
 
Patients who have come into contact with the healthcare system are at risk for HA-
MRSA. Risk factors for HA-MRSA include prolonged hospitalization, stay in the 
intensive care unit (ICU), prolonged antimicrobial therapy, surgical procedures, and close 
proximity to a patient in the hospital who is infected or colonized with MRSA. HA-
MRSA is often multidrug resistant and causes pneumonias and BSIs.2,9,10 Roughly 40-
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50% of hospital-acquired S. aureus isolates are methicillin-resistant.9 CA-MRSA is 
acquired from coming into direct contact with the organism through skin-to-skin contact 
with infected or colonized individuals or contaminated fomites. While some of these 
individuals may have come into contact with the healthcare system, there have been 
reports of community-acquired SSTIs in correctional facilities, military personnel, day-
care centers, men-who-have-sex-with-men, and athletes.11,12 CA-MRSA usually causes 
SSTIs, and can be responsible for necrotizing pneumonia and osteomyelitis.2,11 CA-
MRSA most often contains SCCmec type IV which also carries other virulence factors.2,4 
CA-MRSA is resistant to beta-lactam antibiotics, but the other Gram positive-active 
agents – which are discussed later – retain much activity against CA-MRSA.11 From a 
predominantly community-acquired S. aureus cohort, 42% of isolates from the 
bloodstream and 58% of isolates from wounds or abscesses were methicillin-resistant.13 
 
Because it is a commensal organism that has the potential to cause opportunistic 
infections, incidence of S. aureus infection is high. A study using administrative data 
from The Surveillance Network (TSN) Database-USA estimated the rate of S. aureus-
related hospitalizations at 17.68 per 1,000 hospitalizations in 2009.14 A study of health 
plan beneficiaries demonstrated the rate of S. aureus SSTIs to be 142.8 per 100,000 years 
and the rate of S. aureus bacteremia (SAB) to be 4.7 per 100,000 patient years.13 One 
population based study out of Minnesota estimates an annual incidence of S. aureus 
bacteremia (SAB) of 38.2 per 100,000 person-years over the period between 1998 and 
2005.15 There were no differences in incidence over the seven-year period. However, the 
incidence of MRSA bacteremia increased significantly in this cohort over the studied 
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time period from 4.6 per 100,000 person years in 1998 to 10.8 per 100,000 person years 
in 2005. The authors of this study attributed the increased trend in MRSA to increases in 
incidence of HA-MRSA, however both CA-MRSA and HA-MRSA are highly incident.  
The data from the TSN study estimated a rate of 11.74 per 1,000 hospitalizations for 
MRSA.14 Overall rate of CA-MRSA was 45% while HA-MRSA was 55%. BSI due to 
MRSA was responsible for 1.59 per 1,000 hospitalizations; 64% were HA-MRSA and 
36% were CA-MRSA.  Klevens et al. studied 18 months of data on MRSA reported to 
the CDC’s Emerging Infections Program/Active Bacterial Core surveillance program.16 
Eighty-five percent of MRSA infections were hospital-acquired and 13.7% were 
community-acquired. BSI (75%), pneumonia (13.3%), and cellulitis (9.7%) were the 
most common infectious syndromes in this cohort.16  
 
S. aureus is also a prominent cause of nosocomial infections. In a study of healthcare-
associated infections reported to the Centers of Disease Control and Prevention National 
Healthcare Safety Network for 2009-2010, S. aureus was responsible for 15% of 
healthcare-associated infections, causing over 12,000 infections.9 It was the leading 
causative pathogen for ventilator associated pneumonia and surgical site infections.9 In 
the cohort of 8972 cases of invasive MRSA reported by Klevens et al. above, 26.6% were 
hospital-onset infections.16 Risk factors for hospital-onset MRSA include previous 
hospitalization, history of surgery, long-term care residence, and previous MRSA 
infection or colonization.16 
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Mortality from S. aureus bacteremia is considerable. Overall 30-day mortality rate for is 
estimated at 20% with an attributable mortality rate of 13%, while mortality after one-
year is as high as 62%.17,18 The mortality rate for invasive MRSA infection is estimated at 
6.3 per 100,000 patients with higher mortality in persons 65 years and older, African 
Americans, and males.16 Multivariate analysis of 1600 episodes of SAB from a 
retrospective database identified risk factors of mortality to include advanced age, female 
gender, pneumonia or unknown source of infection, dementia, Charlson score, shock at 
onset, and arrival to hospital from an institution.18 
 
Risk factors for S. aureus infection include immunocompromised state, diabetes, 
substance abuse, and age.2,14,19 Young persons under the age of 20 years overall had 
lower hospitalization rates for MRSA than older patients.14 One risk factor that largely 
contributes to risk is presence of an intravascular catheter used for dialysis. A study 
utilizing 2008 data from the CDC’s Emerging Infections Program/Active Bacterial Core 
surveillance system estimated the rate of healthcare-associated, community-onset MRSA 
bloodstream infections at 404 cases per 10,000 person-years among patients who 
received dialysis within one year compared to 1.62 cases per 10,000 person-years in all 
patients included in the database.20 Intravenous drug users (IVDUs) are at increased risk 
for S. aureus infections due to increased prevalence of nasal colonization, use of 
contaminated drugs and paraphernalia, and close personal contact within the drug use 
environment.21,22 One incidence study conducted in Detroit, MI, showed that S. aureus 
was the causative pathogen in 57% of infections in a cohort of IVDUs with 42% of those 
S. aureus isolates being resistant to methicillin.23  
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Given the high incidence of S. aureus infection and high mortality rate, maintaining an 
effective armamentarium of antistaphylococcal antibiotics is paramount to preventing 
these rates from increasing. Cell-wall active and rapidly bactericidal agents such as beta-
lactams remain the drug of choice against S. aureus.24 Due to the previously described 
resistance to beta-lactams, other agents with different mechanisms of action have been 
developed. The virulent and adaptable S. aureus has developed resistance to all of them. 
Presence of the erm gene confers resistance to macrolides, lincosamides, and 
streptogrammin B through alteration of the ribosomal target site on S. aureus.4 
Macrolides and sreptogrammins are also susceptible to drug efflux if the msrA gene is 
present.4 Resistance to the protein synthesis inhibitor linezolid occurs in the presence of 
the cfr gene. This target site-modifying gene confers cross-resistance to chloramphenicol 
and clindamycin.2,4 S. aureus develops resistance to fluoroquinolones thanks to selective 
pressure when this Gram-positive bacterium is introduced to subtherapeutic 
concentrations from doses used to treat a concomitant Gram-negative infection. S. aureus 
develops mutations at the target enzymes in the DNA synthesis process that are inhibited 
by fluoroquinolones.25 The folate antagonist combination trimethoprim/sulfamethoxazole 
(TMP/SMX) becomes ineffective against S. aureus when the organism upregulates 
production of the sulfonamide target p-aminobenzoic acid or decreases the binding 
affinity for trimethoprim to dihydrofolate reductase.25 
 
Once the mutated PBP-2a was elucidated as the cause of methicillin resistance in S. 
aureus, this became the target for new beta-lactam development. In 2010, ceftaroline 
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fosamil was approved for the treatment of SSTIs and community-acquired pneumonia.26-
28 This is the first widely available beta lactam to target the mutation in MRSA, 
developed almost 50 years after the PBP mutation was discovered. Yet its clinical 
applications are limited. Its use in clinical practice is often as a second or third line agent 
for MRSA bacteremia, sometimes in combination with another agent.29-31 Data on 
ceftaroline in bacteremia is limited to observational studies and registry databases.30,32 
Ceftaroline binds with high affinity to the mutated PBP-2a in MRSA and thus requires a 
lower minimum inhibitory concentration (MIC) for clinical success.33 However, resistant 
isolates have already emerged during its short period of clinical use.34  
 
Vancomycin was first approved in 1958 for treatment of penicillin-resistant S. aureus, but 
after the approval of antistaphylococcal beta-lactams, it became a second line agent.35 It 
became a first line agent in the 1980s as MRSA began to emerge and has been widely 
used since that time.36 Sorrell et al. described vancomycin for the treatment of MRSA 
bacteremia in 10 patients and saw no differences in mortality or relapse compared to 
patients with MSSA who received a beta-lactam.37 Levine et al. described a cohort of 23 
patients with IE caused by CA-MRSA who were treated with vancomycin or a 
combination of antibiotics including vancomycin and surgery.38 Sixty-one percent of 
patients were cured. It exerts its activity by binding to D-alanyl-D-alanine terminal 
peptide of the peptidoglycan precursors, thus preventing cross-linking in the bacterial cell 
wall.39 Compared to beta-lactam agents, vancomycin is slowly bactericidal with a median 
time to resolution of positive blood cultures of 9 days.40 Vancomycin requires 
pharmacokinetic monitoring to ensure both therapeutic efficacy and to monitor patient 
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safety.41,42 It is considered a time-dependent killer where optimizing the duration of time 
that serum concentrations are at a therapeutic level increases antimicrobial effect. When 
examining a concentration versus time curve, the pharmacodynamic parameter to 
optimize is a ratio of area-under-the-curve (AUC) to MIC with most studies supporting 
an optimal AUC/MIC ratio of 400.43,44 (see Fig. 1.1)  
 
Figure 1.1: Pharmacokinetic and pharmacodynamic illustration of vancomycin.  
Concentration (mg/L) is along y-axis and time in hours is along the x-axis. AUC24=area 
under the curve over 24 hours (mg/L). MIC=minimum inhibitory concentration 
(mg/L).45,46   
 
 
Unlike other agents that have been developed to combat S. aureus, vancomycin has 
largely retained its activity over this period of time. In the last 15 years, only 14 isolates 
of vancomycin-resistant strains of S. aureus have been identified globally, with the 14th 
being confirmed in 2015.47 Vancomycin resistance is mediated by the plasmid-mediated 
vanA gene, which causes an amino acid substitution from the D-alanyl-D-alanine target 
site to D-alanyl-D-lactate, preventing vancomycin binding.48 S. aureus acquired this 
resistance mechanism through horizontal transmission from Enterococcus, an organism 
with which vancomycin resistance is more common.48,49  
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Importantly, a more common clinical scenario is S. aureus strains that are intermediately 
sensitive to vancomycin. This occurs due to changes in the bacterial cell wall leading to 
increased cell wall thickness and overproduction of D-alanyl-D-alanine target site. This 
causes vancomycin to become effectively sequestered in the cell wall of the bacteria and 
ultimately ineffective.48,50 One phenomenon that is increasing in prevalence is 
heterogeneous vancomycin intermediate S. aureus (hVISA) where vancomycin-resistant 
subpopulations exist among predominantly susceptible strains, resulting in increased 
MICs and failure of vancomycin therapy.50  Prevalence of hVISA was estimated at 1.2% 
from a 2011 study of MRSA isolates.51 Risk factors for developing hVISA include 
previous vancomycin exposure, high inoculum infections, persistent bacteremia, and 
subtherapeutic vancomycin serum concentrations.52-54 HVISA may preclude VISA with 
repeated vancomycin exposure exerting selective pressure favoring the subpopulations 
with higher MICs.55,56 Previous vancomycin exposure and subtherapeutic vancomycin 
concentrations may play a role in decreased susceptibility with other agents, as will be 
discussed in a review of daptomycin. 
 
HVISA is speculated to play a role in therapy failure of vancomycin against S. aureus 
when the MIC is at the upper end of the susceptibility range, as reported in multiple 
studies.57-60  This led to the 2006 decision by the Clinical Laboratory and Standards 
Institute to change the vancomycin breakpoints for S. aureus so that an MIC <2 mg/L 
was considered susceptible, 4-8 mg/L is considered intermediate, and MIC >16 mg/L is 
considered resistant.54 Additionally, multiple centers reported an overall increase in the 
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vancomycin MICs of the S. aureus isolates they were encountering clinically.61-64 This 
phenomenon is referred to as the MIC creep. A large study using isolates from 
international surveillance data from multiple sites of infection was not able to corroborate 
the occurrence of the MIC creep, however individual centers’ epidemiological and 
clinical factors and susceptibility testing procedures must be considered.65,66 
 
With the 2006 changes in vancomycin breakpoints, the accuracy of the different 
susceptibility testing procedures must be considered in determining the impact of this 
vancomycin MIC creep. The gold-standard method for determining MIC is broth 
microdilution (BMD).67 However, this labor intensive and time consuming methodology 
is prohibitive to most clinical microbiology labs. As a result, various automated BMD 
testing methods are available. Compared to standard BMD-identified MIC, manual 
epsilometer testing (E-testing) and the automated methods may underestimate or 
overestimate the true MIC.68-70 This is especially problematic when vancomycin MICs 
are closer to 2 mg/L. Rybak and colleagues showed 80% agreement between E-testing 
and BMD when the vancomycin MIC equals 2 mg/L while the automated testing 
methods ranged from 20%-92% agreement.68 Bland and colleagues showed that 87% of 
MRSA isolates had higher vancomycin MICs as determined by E-test than determined by 
the automated method.69 Hsu and colleagues looked at vancomycin MIC reporting and 
clinical outcomes in MRSA infections.70 In their cohort of patients with MRSA 
infections, 17 of 21 patients who failed vancomycin therapy had MICs as determined by 
E-testing >1 mg/L. The agreement between other susceptibility testing methods and E-
testing when the MIC >1 mg/L ranged from 9%-80%. The study authors saw more 
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vancomycin failures at a higher MIC, and E-testing was the most accurate way to 
determine MIC with a positive predictive value of 89%.70  Some centers have moved 
toward E-testing bloodstream isolates of MRSA for a more accurate estimation of 
vancomycin MIC. However, E-testing tends to be conservative and is interpreted 
subjectively by microbiology laboratory personnel.  
 
In attempts to answer the question regarding clinical implications of vancomycin MICs at 
the upper limit of susceptibility in S. aureus infections, multiple meta-analyses have been 
conducted. Three of these meta-analyses concluded that there in an increased risk of 
mortality and treatment failure with high, but susceptible vancomycin MICs against S. 
aureus.71-73 However, these meta-analyses are limited by heterogeneous definitions of 
treatment failure among included studies, different antimicrobial susceptibility testing 
methods, and multiple sites of infection. In the prominent meta-analysis by van Hal and 
colleagues the authors stated that their findings were driven by BSIs with vancomycin 
MIC >2 mg/L by E-test.72 A more recent meta-analysis conducted by Kalil and 
colleagues attempted to specifically examine the driver of treatment failure as defined by 
van Hal.74 Their meta-analysis included only S. aureus BSIs where the susceptibility was 
tested by broth microdilution or E-test and examined all-cause mortality as a primary 
outcome. Analysis did not find an increased absolute risk of mortality when the 
vancomycin MIC was >1.5 mg/L. The findings by Kalil and colleagues support current 
Infectious Diseases Society of America (IDSA) recommendations against using 
vancomycin MIC only to drive therapy decisions and instead use clinical assessment for 
management of patients with MRSA bacteremia.75 
12 
 
 
One rationale for treatment failure at these MICs includes limited ability to reach 
pharmacodynamic targets for optimal bactericidal activity using safe medication doses. 
As previously mentioned, the pharmacodynamic target for vancomycin therapy is an 
AUC/MIC ratio of 400. Patel and colleagues performed Monte Carlo simulations to 
determine both the probability of achieving this pharmacodynamic target at various 
vancomycin MICs and the probability of nephrotoxicity at various vancomycin dosing 
regimens.76 They found that in MRSA infections with vancomycin MIC of 2 mg/L, in 
order to achieve AUC/MIC > 400 80% of the time, one must employ a vancomycin 
dosing regimen of 2000mg every 12 hours. However, this dosing regimen was associated 
with a 14% chance of nephrotoxicity in non-ICU patients and a 34% chance of 
nephrotoxicity in ICU patients.  The scenario in which higher doses are required to 
achieve therapeutic efficacy must be balanced with minimizing adverse events of 
vancomycin therapy.  
 
Though vancomycin has remained efficacious over time, the aforementioned safety and 
monitoring limitations led clinicians to develop daptomycin, which is not associated with 
nephrotoxicity and requires less monitoring. Daptomycin carries indications for SSTI and 
BSI due to S. aureus.77,78 It has a faster bactericidal mechanism of action and, is 
administered once daily.79 Initially developed in 1986, clinical trials were halted due to 
high occurrence of myalgias and creatine kinase (CK) elevations seen when the drug was 
administered multiple times per day.79,80 A new investor and carefully designed safety 
trials resurrected daptomycin and in 2003 it was approved by the FDA for SSTI.77 It 
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works by forming a cationic complex with calcium and binding to bacterial membranes, 
causing rapid depolarization of membrane potential.81  
 
Daptomycin is approved for the treatment of SAB and right-sided IE at a dose of 6 mg 
per kilogram (kg), however higher doses have been studied. In the randomized controlled 
trial that garnered its approval, daptomycin 6 mg/kg per day was compared to 
vancomycin for clinical success at the end of 42 days of therapy. There was no difference 
between treatment groups with an absolute difference in success rates of 3.4% (95% CI -
8.9-15.7).78 In utilizing the concentration-dependent pharmacodynamics of daptomycin, 
higher doses have shown good rates of success and low rates of adverse effects. Kullar et 
al. studied daptomycin dosed 8-10 mg/kg in 250 patients with Gram positive infections 
and observed an 83.6% clinical success rate.82 Adverse effects in this cohort were rare 
with 1.2% of patients experiencing adverse effects and only one patient requiring dose 
reduction due to CK elevations. A study of 94 registrants from the post-marketing 
Cubicin Outcome Registry Experience database who received daptomycin 8 mg/kg for 
Gram positive infections demonstrated an 89% cure rate in clinically evaluable 
registrants.83 Adverse effects related to daptomycin occurred in 6.4% of patients 
including CK elevations occurring in 3.2% of patients, however, these were all deemed 
not clinically relevant. High-dose daptomycin is efficacious without increased rates of 
adverse events, and high doses are often utilized in clinical practice. 
 
Since the study by Fowler and colleagues that secure its indication for bacteremia, no 
clinical trials have demonstrated daptomycin’s superiority to vancomycin. However, 
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some single center, retrospective studies indicate that it may be superior in certain clinical 
situations. One study by Moore and colleagues examined patients with S. aureus who 
were changed to daptomycin therapy and matched them to patients who completed 
therapy with vancomycin based on age, Acute Physiology and Chronic Health Evaluation 
II score, and risk level of source.84 The decision to change therapy was based on a 
vancomycin MIC of 1.5 or 2 mg/L as determined by E-test and use of daptomycin at the 
time was restricted to infectious diseases service. Patients who were switched to 
daptomycin were switched at a median time of 5 days and the majority was switched due 
to lack of improvement or worsening on vancomycin. There were no statistically 
significant differences between groups in a composite outcome of 60-day mortality, 
microbiological failure, and recurrence (P=0.084), however 60-day mortality was 
significantly lower (20% vs. 9%, P=0.046) in the group that was switched to 
daptomycin.84 Because treatment changes were at the discretion of the treating physician, 
there may have been selection bias where patients with higher MICs or who were 
expected to do worse were switched to daptomycin. Additionally, there may have been 
other factors contributing to poor outcomes. For instance, the study authors did not 
comment on control of the source of infection between treatment groups. This study does 
contribute to the question of vancomycin’s efficacy against MRSA with higher MICs and 
whether this may be a potential role for daptomycin. 
 
 In another study, Murray and colleagues studied outcomes with early switch to 
daptomycin based on vancomycin MIC.85 In accordance with an institutional policy, 
patients who had MRSA with a vancomycin MIC >1 mg/L received daptomycin as soon 
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as microbiological susceptibility data was available. Patients who received daptomycin 
were matched by age, Pitt bacteremia score, and source of bacteremia to patients who 
received vancomycin. Median duration of vancomycin therapy prior to daptomycin was 
1.7 days. Crude analysis showed that daptomycin was superior to vancomycin in a 
composite outcome of 30-day mortality and occurrence of persistent bacteremia (20% vs. 
48.2%, P<0.001). This difference remained in multivariable logistic regression where 
vancomycin patients had 4.5 times higher odds of clinical failure compared to 
daptomycin. However, one limitation to this study is a change in practice standards as 
microbiology testing methods changed from E-test to MicroScan during the study period. 
These susceptibility testing methods are known to have different accuracy in estimating 
vancomycin MIC.68 This study excluded central venous access-related infections, so most 
clinical failures were in deep-seated infections such as IE and bone or joint infections.85 
Widespread application of these studies is limited in that they represent the patient 
population in one urban city with few comparative studies from other centers. The early 
transition to daptomycin and minimization of vancomycin exposure resulting in better 
outcomes is interesting, and the present study seeks to determine if that time to switch 
plays a role in clinical outcomes.  
 
Decreased susceptibility to daptomycin was seen in the study by Murray and colleagues 
where 2.6% of patients receiving daptomycin experienced elevated MICs into the non-
susceptible range while on therapy.85 In the clinical trial by Fowler and colleagues, 5% of 
patients developed reduced susceptibility to daptomycin while on treatment.78 
Daptomycin non-susceptibility (DNS) in S. aureus has emerged in less than 10 years 
16 
 
since the antibiotic’s approval with the first isolate identified in 2003.86 DNS is mediated 
by two mechanisms: an increase in the positive charge of the cell membrane and 
increased cell wall thickness.87,88 This increased positivity repels the calcium-daptomycin 
complex and prevents the antibiotic from getting to its site of action. Increased cell wall 
thickness prevents daptomycin from reaching the cell membrane. Both resistance 
mechanisms effectively prevent membrane depolarization and leakage of cell contents 
leading to cellular death. The clinical understanding of factors leading to emergence of 
DNS is controversial. While some studies have suggested that it is related to vancomycin 
exposure, this is an area of continued exploration since results of studies have been 
mixed.87,89-91 The potential association between vancomycin exposure and DNS is 
troubling since clinical guidelines and practice patterns advocate for the use of 
vancomycin first line followed by daptomycin in patients who experience clinical decline 
or failure on vancomycin therapy.75,92  
 
Decreased daptomycin susceptibility has been observed in VISA isolates. Sader and 
colleagues examined 207 previously collected S. aureus isolates and observed that 47% 
of VISA isolates were also DNS with MICs > 1mg/L, in contrast to 100% of wild-type 
MRSA and 100% of hVISA retaining daptomycin susceptibility.93 Though all hVISA 
isolates in this study retained susceptibility to daptomycin, hVISA can preclude VISA 
and thus by extension may preclude DNS.55 Patel and colleagues reviewed 917 S. aureus 
isolates sent to the CDC.94 Of 70 isolates with vancomycin MIC between 4 and 16 mg/L, 
almost 83% of them were DNS.94 An in vitro study by Sakoulas and colleagues 
demonstrated both development of a vancomycin intermediate phenotype and increasing 
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daptomycin MICs after 4 isolates of MRSA were exposed to vancomycin.89 It stands to 
reason that daptomycin would have decreased activity against VISA because increased 
cell wall thickness is one of the mechanisms behind DNS and contributes to VISA.88,95  
 
The impact of previous vancomycin exposure on daptomycin susceptibility in S. aureus 
isolates with retained vancomycin activity is less replicable. Moise and colleagues 
conducted a study of 81 clinical MRSA isolates that showed a statistically significant 
relationship between elevated vancomycin MICs and previous vancomycin exposure 
(P=0.002) but this relationship was not demonstrated with daptomycin MICs 
(P=0.111).87 While Bhalodi and colleagues were able to demonstrate reduced daptomycin 
activity against an MRSA isolate in vitro after the isolate was exposed to vancomycin for 
48 hours, they did not detect new DNS subpopulations.90 Using 5 clinical S. aureus 
isolates that had reportedly become DNS, Rose and colleagues exposed isolates in vitro 
to vancomycin for 4 days followed by daptomycin simulated at 6 mg/kg or 10 mg/kg for 
4 days.91 Daptomycin retained activity against all strains with no difference in time to 
achieve 99.9% killing between vancomycin pre-exposed and un-exposed simulations. 
However, daptomycin was more potent against strains that were not pre-exposed to 
vancomycin.  
 
Until concrete evidence can be elucidated regarding the effect of vancomycin exposure 
on daptomycin susceptibility in S. aureus, clinicians should be optimizing management 
of S. aureus infections to preserve daptomycin’s clinical utility and prevent emergence of 
DNS. Key clinical interventions include taking advantage of concentration-dependent 
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activity to maximize daptomycin exposure by utilizing high doses, performing early 
surgery on deep-seated infections with high inoculum to achieve source control, and 
maintaining therapeutic vancomycin exposure.92 
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CHAPTER TWO: RATIONALE, OBJECTIVES, and SIGNIFICANCE 
 
Staphylococcus aureus is an aerobic, Gram positive bacterium naturally found as a 
commensal organism on the skin of humans that can become an opportunistic pathogen 
capable of causing a wide spectrum of disease.2 With its introduction into clinical 
practice in 1940, penicillin revolutionized the treatment of infectious diseases, including 
S. aureus; however resistance emerged as soon as 1942.6 In 1959, antibiotics that 
remained stable against degrading enzymes produced by the organism were developed, 
yet in 1961, methicillin-resistant isolates of S. aureus began to emerge.8 Though many 
antibiotics have been developed to combat S. aureus, the organism has developed 
resistance to most of them and thus they are not utilized first line like vancomycin.  
 
Community-acquired (CA-MRSA) and hospital-acquired (HA-MRSA) cause distinct 
infectious syndromes in different patient populations. Annual incidence of SAB is 
estimated between 4.7 and 38.2 per 100,000 patient-years.13,15 S. aureus was responsible 
for over 12,000 nosocomial infections from 2009-2010.9 Mortality from SAB is 
considerable with an overall 30-day mortality rate estimated at 20% and mortality after 
one-year as high as 62%.17,18 Risk factors for S. aureus infection include 
immunocompromised state, diabetes, substance abuse, age, presence of central venous 
catheters, and IV drug use.2,14,19,20,23  
 
Vancomycin has been widely used since the 1980s demonstrated an increasing incidence 
of MRSA, and little resistance has developed in the last 30 years. However, S. aureus has 
developed decreased susceptibility to the drug through alterations in cell wall thickness 
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and overproduction of antimicrobial targets.48,50 Individual S. aureus microbes with 
decreased susceptibility can exist as subpopulations of an otherwise susceptible isolates, a 
phenomenon known as hVISA. Heteroresistance is speculated to play a role in therapy 
failure of vancomycin against S. aureus and an epidemiologic shift to more S. aureus 
isolates have MICs at the upper end of the susceptibility range; however the accuracy of 
different susceptibility testing procedures must be considered in determining the impact 
of this vancomycin MIC creep.68-70 One rationale for treatment failure at higher MICs 
includes limited ability to reach pharmacodynamic targets for optimal bactericidal 
activity using safe medication doses.76 The need to balance the use of efficacious dosing 
while minimizing adverse events has led individual clinicians to choose alternative 
therapeutic agents for treatment of MRSA BSI.  
 
Daptomycin carries indications for SSTI and BSI due to S. aureus, is not associated with 
nephrotoxicity, and requires less monitoring. While practice guidelines endorse 
daptomycin as an alternative to vancomycin, no clinical trials have demonstrated 
superiority of daptomycin to vancomycin. Current clinical guidelines support a change in 
therapy guided by patient clinical status.75 Some single-center studies have suggested 
better outcomes with daptomycin against SAB with higher vancomycin MICs or when 
switched early in treatment course.84,85 Daptomycin non-susceptibility has been 
encountered clinically and some studies suggest it may be related to previous vancomycin 
exposure. VISA strains have demonstrated DNS, but this has been less replicable with 
hVISA strains and vancomycin susceptible strains.87,89-91,93,94 
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The primary objective of this study is to compare clinical outcomes in patients receiving 
treatment for S. aureus bacteremia who switch from vancomycin to daptomycin early 
(after 1-3 days), intermediately (after 4-7 days), or late (after 8 days or more) in 
treatment. The central hypothesis of this study is that there are differences in clinical 
outcomes among patients who switched from vancomycin to daptomycin early, 
intermediately, and late in therapy for S. aureus bacteremia. Clinical failure was defined 
as recurrent positive blood cultures for S. aureus within 30 days of first positive blood 
culture, death within 60 days after first blood culture positive for S. aureus, and all-cause 
readmission within 90 days after first blood culture positive for S. aureus.  
 
Secondary outcomes were to describe the patient population that is switched early, 
intermediately, and late and to determine what patient factors are associated with 
treatment failure. Data collected to describe these patients include demographic 
characteristics, comorbidity measures, severity of illness measures, infection 
characteristics, concomitant antibiotics received, and safety outcomes measures. 
Multivariable logistic regression models were constructed to determine independent 
patient factors associated with treatment failure. 
 
This study is significant because it contributes to previously published literature 
regarding daptomycin versus vancomycin use in S. aureus bacteremia. It further explores 
previously hypothesized relationships between vancomycin MIC and daptomycin use, 
and time to switching to daptomycin and patient outcomes. Previous meta-analyses have 
raised questions regarding vancomycin efficacy in SAB when the vancomycin MIC is 
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greater than 1 mg/L, and have hypothesized that this could be a niche for daptomycin.17 
One retrospective observational study showed that when vancomycin is switched to 
daptomycin early based on higher vancomycin MIC, the patients switched to daptomycin 
had lower clinical failure rates.85 Patients from this study would fall into the early therapy 
switch of the present study, and early switch patients will be compared directly to 
patients who are on vancomycin for a longer period before switching. Additionally, the 
distribution of vancomycin MICs for S. aureus isolates will be observed among groups 
and if there any differences in outcomes. Another retrospective study showed a mortality 
benefit when switching from vancomycin to daptomycin intermediately in treatment.84 
The present study will help bridge knowledge gaps from these previous studies by being 
the first to directly compare patients initiated on vancomycin and switched to daptomycin 
at different time frames. This study helps determine if the extent of previous vancomycin 
exposure before switching to daptomycin plays a role in clinical outcomes.  
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CHAPTER THREE: METHODS 
 
Study Design 
A retrospective cohort design was utilized for this study. Patients were included if they 
were at least 18 years of age at the time of admission, admitted between January 1, 2010, 
and December 31, 2014, received vancomycin and daptomycin during hospitalization, 
had an International Classification of Diseases, 9th revision (ICD-9) code of interest billed 
for during admission, and had S. aureus identified from blood culture. Only the first 
admission per patient during that time period was included for analysis. 
 
Since the study investigator examined patients who were initiated on vancomycin and 
then therapy was changed to daptomycin, patients had to receive both medications. 
Medication administration data was utilized to determine duration of therapy. In order to 
adequately ascertain clinical outcomes, patients were excluded if the total duration of 
vancomycin and daptomycin was less than 3 days. 
 
ICD-9 codes used to determine enrollment were V09.0 “infection with microorganisms 
resistant to penicillin”, 038.11 “S. aureus septicemia”, 038.12 “Methicillin resistant S. 
aureus septicemia”, 041.11 “S. aureus infection, site unspecified”, or 041.12 “Methicillin 
resistant S. aureus infection, site unspecified”.96 
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Data Source 
Subjects were identified and data was collected using the University of Kentucky (UK) 
Enterprise Data Trust (EDT) through the Center for Clinical and Translational Science 
(CCTS), which is supported by the National Center for Advancing Translational 
Sciences, National Institutes of Health, through grant number UL1TR000117. The CCTS 
EDT is maintained by a biomedical informatics team and the Institute for Pharmaceutical 
Outcomes and Policy at UK to house clinical data from different electronic systems at 
UK HealthCare (UKHC). As of December 2015, the clinical data set currently 
encompasses 554,300 lives admitted as inpatients to UKHC from 2006 on.97 The EDT 
has search dimensions for information on demographics, financial classification, provider 
level detail, medical diagnosis (ICD-9 standard), medical procedures (current procedural 
terminology [CPT] codes), laboratory tests and results, medications administered, visit 
details, and vital signs. The UK Institutional Review Board (IRB) has granted umbrella 
approval for the use of de-identified EDT data for research purposes, and the current 
study was approved by the UK IRB for use of identified EDT data. Clinical data was 
collected on identified subjects and is listed in Appendix A. CPT codes for source control 
procedures are listed in Appendix B. Specific data source variables used in the project are 
detailed in Appendix C. 
 
 
 
25 
 
Definitions 
Patients were stratified based on time to change in therapy from vancomycin to 
daptomycin.  They were a priori assigned to the early switch group if therapy was 
changed after 1-3 days on vancomycin therapy, the intermediate switch group if therapy 
was changed in 4-7 days, or late switch group if therapy was changed at 8 days or longer.  
 
Time to positive cultures reflects the length of time from admission to diagnosis of 
bloodstream infection by positive cultures. 
 
A patient was determined to have other infectious organisms if an organism other than S. 
aureus grew from subsequent blood cultures or other tissue samples. Contaminants and 
colonization were excluded from the definition of other infectious organisms. An isolate 
was determined to be a contaminant if it grew in blood from only one bottle in a set and 
did not undergo further microbiological work-up. Isolates determined to represent 
colonization include Candida species or Enterococcus species isolated from respiratory 
sources, less than 100,000 colony-forming units (CFU) of organism from urine, and less 
than 10,000 CFU of organism isolated from respiratory source. The presence of enteric 
Gram negative organisms, Enterococcus species, or Candida species from stool culture 
also was considered colonization as these organisms represent normal flora. 
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Treatment failure is defined as all-cause mortality at 60 days from first positive blood 
culture, recurrence of S. aureus in bloodstream within 30 days from initial clearance of 
blood cultures, or all-cause readmission within 90 days.  
 
Outcomes 
The primary outcome is treatment success or treatment failure. Secondary outcomes 
included the assessment of each individual component defining treatment success or 
failure and safety outcomes (development of renal injury per RIFLE criteria, diagnosis 
with Clostridium difficile infection, and rhabdomyolysis or creatine kinase elevation 
>1500 units/mL). Rhabdomyolysis was identified using the ICD-9 code 728.88 
“rhabdomyolysis”.98 Use of the ICD-9 code 00.845 “intestinal infection due to C. 
difficile” has been shown to be highly sensitive and specific for identifying C. difficile 
infection.99 
 
RIFLE is an acronym for risk of renal dysfunction, injury to the kidney, failure of kidney 
function, loss of kidney function, and end-stage kidney disease. It is a classification 
system for assessing acute renal failure. It considers change from baseline, acute on 
chronic renal disease, sensitivity and specificity, and can be applied across multiple 
centers.100 Table 3.1 describes the RIFLE classification for acute renal failure. 
Glomerular filtration rate was calculated using a modified Cockcroft-Gault equation that 
omitted body weight from the equation.101 Temporality for defining loss of kidney 
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function and end-stage kidney disease could not be assessed, therefore only risk, injury, 
and failure were assessed as acute kidney injury. 
 
Table 3.1: Classification scheme for acute renal failure per RIFLE criteria100 
Class 
Glomerular Filtration Rate (GFR) 
Criteria 
Urine Output Criteria 
Risk 
Increased SCr x1.5 or GFR decrease 
>25% 
<0.5 mL/kg/hr x6 hours 
Injury 
Increased SCr x2 or GFR decrease 
>50% 
<0.5 mL/kg/hr x12 hours 
Failure 
Increase SCr 3x or GFR decrease 
75% or SCr >4 mg/dL 
<0.3 mL/kg/hr x24 hours or 
anuria x12 hours 
Loss Persistent acute renal failure >4 weeks 
End-stage 
kidney disease 
Complete loss of kidney function >3 months 
 
Statistical Analysis 
All statistical comparisons were performed using SAS® version 9.3 (Cary, NC) statistical 
software. A Shapiro-Wilks test was performed to determine normality and all variables 
were found to be statistically significantly different from normal, thus nonparametric 
statistical tests were employed for analysis. Baseline descriptive statistics are reported as 
median and interquartile range for continuous data or proportions for categorical data. 
Fisher’s exact test will be used to compare distribution of categorical data. Wilcoxon rank 
sum test will be used to compare distribution of continuous data. The analysis of variance 
(ANOVA) test was used to compare multiple groups. An alpha level of <0.05 was set to 
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determine statistical significance. To determine independent predictors of success, a 
multivariable logistic regression model will be constructed to determine odds ratios with 
clinical success as the outcome of interest. Backward elimination with an alpha 
significance level of 0.05 was carried out to determine the final model. The Akaike 
Information Criterion (AIC) and AUC were used to determine the most predictive model. 
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CHAPTER FOUR: RESULTS 
 
There were 2,784 admissions for adult patients hospitalized between January 1, 2010, and 
December 31, 2014 billed for at least one of the including ICD-9 codes. Of those ICD-9 
codes, 0.7% of encounters were encoded for V09.0 “infection with microorganisms 
resistant to penicillin, 7.5% were coded for 038.11 “S. aureus septicemia”, 10% were 
coded for 038.12 “methicillin-resistant S. aureus septicemia”, 34.4% were coded for 
041.11 “S. aureus infection, site unspecified”, and 51% were encoded for 041.12 
“methicillin-resistant S. aureus, site unspecified”.  Three hundred sixty seven patients 
received at least one dose of both vancomycin and daptomycin. Of that 367, 195 had 
blood cultures positive for Staphylococcus aureus.  When patients who received less than 
3 days of total therapy were excluded, the final data set included 193 patients. Forty-nine 
patients (25.4%) were in the early switch group, 76 patients (39.4%) were in the 
intermediate switch group, and 68 patients (35.2%) were in the late switch group. 
Baseline characteristics for the final cohort and each treatment group are presented in 
table 4.1. 
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Table 4.1: Baseline characteristics of final cohort, reported as n(%) or median 
(interquartile range) 
 Total 
Cohort 
N=193 
Early 
N=49 
Intermediate 
N=76 
Late 
N=68 
P-
value 
Gender 
   Male 
   Female 
 
119 (62%) 
74 (38%) 
 
30 (61%) 
19 (39%) 
 
49 (64%) 
21 (36%) 
 
40 (59%) 
28 (41%) 
 
0.77 
Race 
   White 
   African American 
   Other 
 
171 (89%) 
17 (9%) 
5 (2%) 
 
43 (88%) 
5 (10%) 
1 (2%) 
 
71 (93%) 
3 (4%) 
2 (3%) 
 
57 (84%) 
9 (13%) 
2 (3%) 
0.31 
Age, years 48 (35-59) 50 (36-59) 45.5 (35-59.5) 48 (35-
58) 
0.68 
Charlson 
comorbidity index 
4 (3-7) 5 (3-8) 4 (3-7) 4 (3-6) 0.52 
Admitted to intensive 
care unit 
26 (13%) 5 (10%) 10 (13%) 11 (16%) 0.67 
History of 
intravenous drug use 
34 (18%) 8 (16%) 16 (21%) 10 (15%) 0.60 
Cardiac prosthesis 9 (5%) 2 (4%) 6 (8%) 1 (1%) 0.23 
Time to positive 
culture, days 
2.9 (2.0-5.1) 2.1 (1.8-
3.5) 
2.2 (1.8-3.3) 4.0 (2.0 
– 10.0) 
0.0005 
MRSA 142 (74%) 29 (59%) 64 (84%) 49 (72%) 0.008 
Vancomycin MIC, 
mg/L 
   1 
   2 
 
 
160 (83%) 
31 (16%) 
 
 
35 (73%) 
12 (25%) 
 
 
57 (80%) 
14 (20%) 
 
 
65 (96%) 
3 (4%) 
0.0016 
Daptomycin MIC, 
mg/L 
   <1 
   >1 
 
 
189 (98%) 
4 (2%) 
 
 
49 (100%) 
0 
 
 
73 (96%) 
3 (4%) 
 
 
67 (99%) 
1 (1%) 
0.45 
E-test performed 46 (24%) 13 (27%) 23 (30%) 10 (15%) 0.076 
Length of stay, days 24 (13-47) 20 (10-26) 20 (11-39.5) 42 (21.5-
55.5) 
<0.00
01 
Source control 
achieved 
   Cardiac 
   Skin/soft tissue 
   Bone/joint 
   Central venous 
access 
 
71 (37%) 
17 
3 
53 
5 
 
18 (37%) 
1 
0 
14 
3 
 
36 (47%) 
13 
2 
24 
1 
 
17 (25%) 
3 
1 
15 
1 
0.021 
Duration of therapy, 
days 
16 (9-27) 7 (4-16) 13 (8-23.5) 23.5 
(15.5-42) 
<0.00
01 
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Polymicrobial 
bloodstream 
infection 
17 (9%) 3 (6%) 5 (7%) 9 (13%) 0.32 
Other infectious 
organisms 
   Gram negative 
   Gram positive 
 
   Fungal from non-
urinary source 
80 (41%) 
 
52 (27%) 
36 (19%) 
 
14 (7%) 
13 (27%) 
 
8 (16%) 
1 (2%) 
 
3 (6%) 
27 (35%) 
 
18 (24%) 
13 (17%) 
 
2 (3%) 
40 (59%)  
 
28 (38%) 
22 (32%) 
 
9 (13%) 
<0.00
01 
0.0245 
<0.00
01 
0.063 
Concomitant MRSA 
therapy 
   Ceftaroline 
   Gentamicin 
   Rifampin 
   Trimethoprim/ 
Sulfamethoxazole 
 
 
38 (20%) 
31 (16%) 
23 (12%) 
10 (5%) 
 
 
12 (24%) 
8 (16%) 
6 (12%) 
0 
 
 
19 (25%) 
13 (17%) 
10 (13%) 
8 (11%) 
 
 
7 (10%) 
10 (15%) 
7 (10%) 
2 (3%) 
 
 
0.045 
0.94 
0.85 
0.023 
Other antibiotics 
   Cefepime 
   Cefazolin 
   Meropenem 
   Nafcillin 
   Piperacillin/ 
Tazobactam 
   Tobramycin or 
Amikacin 
   Amphotericin 
formulation 
 
63 (33%) 
31 (16%) 
24 (12%) 
32 (17%) 
119 (62%) 
 
29 (15%) 
11 (6%) 
 
17 (35%) 
9 (18%) 
4 (8%) 
11 (22%) 
23 (47%) 
 
4 (8%) 
0 
 
23 (30%) 
13 (17%) 
10 (13%) 
11 (14%) 
45 (59%) 
 
7 (9%) 
4 (5%) 
 
23 (34%) 
9 (13%) 
10 (15%) 
10 (15%) 
51 (75%) 
 
18 (26%) 
7 (10%) 
 
0.85 
0.75 
0.60 
0.47 
0.0069 
 
0.0069 
0.046 
 Daptomycin dose, 
mg/kg 
8.0 (6.0-9.6) 8.6 (6.2-
9.7) 
8.6 (6.0-9.6) 7.7 (6.0-
9.4) 
0.56 
Initial vancomycin 
trough, mg/L 
13.3 (9.3-
23.3 
21.5 (11.2-
29.8) 
13 (8.5-20.6) 13.2 
(9.5-
23.3) 
0.076 
Baseline GFR*, 
mL/min 
80.67 
(45.67-
125.43) 
68.50 
(41.38-
111.86) 
80.67 (51.24-
131.61) 
89.72 
(47.16-
128.26) 
0.14 
Baseline CK, units/L 60.5 (27-
174) 
83 (31.5-
189.5) 
44 (24-134.5) 62 (27.5-
176) 
0.70 
MRSA=methicillin-resistant Staphylococcus aureus 
CK=creatine kinase 
*creatinine clearance calculated by modified Cockcroft-Gault equation 
 
Sixty-two percent of the cohort was male. The racial distribution was representative of 
the largely Caucasian state with whites making up 89%. The cohort was middle aged 
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with a median age of 48 years (IQR, 35-59 years). Thirteen percent of patients were 
admitted to the intensive care unit. A history of intravenous drug abuse was reported in 
18% of patients. Median length of stay was 24 days, but the late treatment switch group 
had a significantly longer length of stay of 42 days (P<0.0001). Median time to positive 
blood cultures from admission was 2.9 days with the late group having a significant 
longer time to positive cultures of 4.0 days (P=0.0005).  
 
Seventy-four percent of patients in the cohort had MRSA bacteremia, with the early 
switch therapy group having a significantly lower proportion of MRSA cases at only 54% 
(P=0.008). While most of these cases (83%) had a vancomycin MIC of 1 mg/L, the late 
group had significantly higher proportion of isolates with a vancomycin MIC of 1 mg/L 
(96%, P=0.0016). MICs were tested by E-test for 24% of all S. aureus isolates. 
Daptomycin susceptibility was 98% for the entire cohort. Median time to collection of 
clear blood cultures was one day. The source of infection was controlled in 37% of the 
cohort with 47% of patients in the intermediate group achieving source control and only 
25% in the late group achieving source control (P=0.021).  
 
Median duration of therapy was 16 days, but duration of therapy was significantly shorter 
in the early group and longer in the late group (7 days vs. 23.5 days, P<0.0001). Forty-
one percent of patients had other infectious organisms identified during hospitalization, 
and there were significant differences between groups with 59% of patients in the late 
group growing at least one concomitant organism. Patients in the late group had 
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significantly more Gram negative, Gram positive, and fungal concomitant organisms 
compared to patients in the early and intermediate groups. Daptomycin dosing was not 
significantly different between groups with a median weight-based dose of 8.3 mg/kg for 
the entire cohort. Median first vancomycin level also did not differ between groups with a 
median level of 13.1 mg/L. Twenty percent of patients also received ceftaroline during 
hospitalization, but this was significantly lower in the late group with only 10% of 
patients receiving concomitant ceftaroline (P=0.045). Five percent of patients received 
concomitant sulfamethoxazole/trimethoprim, but a significant proportion (11%) of those 
patients were in the intermediate group (P=0.023). While the majority of patients (62%) 
in the cohort received piperacillin/tazobactam during hospitalization, there were 
significantly fewer in the early switch group and significantly more in the late switch 
group (47% vs. 75%, P=0.0069). Patients in the late switch group also received 
significantly more amikacin or tobramycin (26% vs. 15%, P=0.0069) and amphotericin 
(10%vs. 6%, P=0.046) during hospitalization than the overall cohort.  
 
Median baseline creatinine clearance was not different between groups with a value of 
98.4 mL/min for the cohort. Median baseline CK value was 60.5 units/L and this did not 
differ between groups. 
 
Treatment outcomes are reported in table 4.2. Treatment failure occurred in 18% of 
patients with no differences between groups. None of the components of the definition of 
treatment failure differed between groups.  
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Table 4.2: Treatment outcomes, reported as n (%)  
 Total 
Cohort 
N=193 
Early 
N=49 
Intermediate 
N=76 
Late 
N=68 
P-
value 
30-day recurrence of S. 
aureus from blood culture 
2 (1%) 1 (2%) 1 (1%) 0 0.72 
60-day mortality 15 (8%) 3 (6%) 6 (8%) 6 (9%) 0.94 
90-day readmission 19 (10%) 6 (12%) 6 (8%)  7 (10%) 0.71 
Treatment failure 34 (18%) 9 (18%) 13 (17%) 12 (18%) 1.0 
 
Multivariate logistic regression analysis was performed. Variables put into the initial 
model were for treatment group, history of IV drug use, vancomycin MIC, ceftaroline 
therapy, sulfamethoxazole/trimethoprim therapy, piperacillin/tazobactam therapy, 
tobramycin or amikacin use, amphotericin therapy, and other infectious organisms 
(Appendix D). When performing backwards elimination and using AIC and AUC to 
determine the final model, time to positive cultures, length of stay, and other infectious 
organisms provided the model with the best fit (table 4.3). When controlling for other 
covariates, logistic regression showed that time to positive cultures and length of stay 
were significant independent predictors of treatment success. For every one day from 
admission until positive cultures, there was a 4% decreased odds of treatment success 
(OR 0.961, 95% CI 0.927 – 0.997). For every one additional day spent in the hospital, 
odds of treatment success increased by roughly 4% (OR 1.036, 95% CI 1.009 – 1.063). 
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Table 4.3: Odds ratios determined by logistic regression results using treatment 
success as the outcome of interest. 
 
Adjusted Odds Ratio 
Estimate 
95% Confidence 
Interval 
 P-value 
Time to positive 
cultures 
0.961 0.927 0.997 0.057 
Length of stay 1.036 1.009 1.063 0.0079 
Other infectious 
organisms 
0.517 0.225 1.184 0.12 
 
Safety outcomes are reported in table 4.4. The incidence of C. difficile was low in the 
cohort with only 2% of patients being diagnosed during admission. Rhabdomyolysis 
occurred in 6% of patients. Nephrotoxicity per RIFLE criteria occurred in 43% of 
patients. There were no differences between groups in occurrence of adverse outcomes. 
Nephrotoxicity was experience by 41% of patients in the early switch group, 35% of 
patients in the intermediate group, and 53% of patients in the late switch group (P=0.1). 
 
Table 4.4: Safety outcomes, reported as n (%)  
 Total 
Cohort 
N=193 
Early 
N=49 
Intermediate 
N=76 
Late 
N=68 
P-
value 
Rhabdomyolysis 12 (6%) 3 (6%) 4 (5%) 5 (7%) 0.93 
Clostridium difficile 3 (2%) 0 1 (1%) 2 (3%) 0.62 
Nephrotoxicity 83 (43%) 20 (41%) 27 (35%) 36 (53%) 0.1 
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CHAPTER FIVE: DISCUSSION 
 
This study of 193 patients with S. aureus bacteremia who initiated treatment on 
vancomycin and were switched to daptomycin found no difference in patient outcomes 
based on time to therapy switch. There was no difference in treatment failure between 
patients switched from vancomycin to daptomycin early after treatment initiation, at an 
intermediate time frame, or late after initiation for SAB. Unlike previous studies, all 
patients in the present study were switched from vancomycin to daptomycin rather than 
having a comparator group that remained on vancomycin. This study accepts the finding 
from Fowler and Moore that daptomycin is non-inferior to vancomycin, but builds upon 
the work of Moore and Murray by attempting to further elucidate when daptomycin 
should be utilized over vancomycin.78,84,85 The treatment failure rate remains roughly 15-
20%, which is consistent with estimates of overall mortality rates of 20%, with mortality 
one component of most study definitions of clinical failure.17,102 
 
Factors that were associated with treatment success were time to positive cultures and 
length of stay. An extended time to positive cultures was associated with decreased 
likelihood of clinical success. S. aureus is one of the most common organisms isolated in 
nosocomial-acquired infections.9 With a median time to positive culture of 4 days in the 
late switch group, most of the BSIs would meet the definition of nosocomial infection, 
where the definition is positive blood culture obtained from patients hospitalized for 48 
hours or longer.103 A study by Klevens et al did not demonstrate a higher mortality rate 
with healthcare-onset SAB vs. community onset SAB, but a study by Cosgrove et al 
showed that nosocomial SAB is associated with significantly longer length of stay.16,102 
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Longer length of stay was associated with increased likelihood of treatment success as for 
each day a patient was admitted to the hospital, the odds of treatment success increased 
by 3%. This is likely a reflection of practice patterns at this institution where patients 
remain in the hospital for a prolonged period of time to complete therapy. A survey of 
hospital medicine and infectious diseases physicians conducted at the University of 
Kentucky revealed that barriers to discharging persons who inject drugs to complete IV 
antibiotic therapy include socioeconomic factors and the potential risk of the patient 
misusing the peripherally-inserted central catheter.104 While participants coded for a 
history of IV drug use represented a smaller proportion and was not associated with 
treatment success in the current study population, IV drug use is a known risk factor for 
developing S. aureus infection.22  
 
Patients in the late switch therapy group had significantly longer lengths of stay than 
patients in the early or intermediate switch group. Significantly lower rates of source 
control and longer durations of antibiotic therapy in the late switch group indicate that 
these patients likely had complicated bacteremia. Source control is the ultimate cure for 
SAB.105-107 The longer length of stay is reflective of the longer duration of antibiotic 
therapy given practice patterns of the institution as previously discussed. While there 
were no differences in Charlson comorbidity index or ICU admission to indicate higher 
severity of illness in the late switch group, these patients more commonly received 
piperacillin/tazobactam, aminoglycosides, and amphotericin during their admission. They 
also had more concomitant Gram negative and Gram positive infections indicating they 
could have had more severe manifestations of infection requiring such broad spectrum 
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coverage. These agents also cause nephrotoxicity when administered concomitantly with 
vancomycin, potentially leading to later switch in therapy as nephrotoxic adverse effects 
began to manifest.60,108-110 This is supported by a trend toward a higher rate of 
nephrotoxicity in the late switch group. Nephrotoxicity has been shown to lead to 
increased lengths of stay.111,112 Charlson comorbidity index, which is a marker of 
expected one-year morality, may not be the best indicator of severity of illness in this 
patient population.113 However, this index was readily available in the administrative data 
set, unlike some other markers of illness severity such as Pitt bacteremia score which 
assesses patients on the day of positive blood cultures and incorporates subjective data 
such as mental status.114 
 
Additional trends where shown between groups with regard to initial vancomycin trough 
and E-test as the susceptibility method performed. Patients in the early switch group had 
a higher median initial vancomycin trough level. The median level seen in that group is 
above the currently recommended therapeutic trough range of 10-20 mg/L.41,115 High 
vancomycin trough levels are associated with higher probability of developing 
nephrotoxicity.60,76,109,116 Patients in this group may have been proactively switched to 
daptomycin earlier in early recognition of the potential for nephrotoxicity, especially 
since they had the lowest baseline GFR. Patients in the late switch group had the lowest 
proportion of S. aureus isolates tested in the clinical microbiology laboratory by E-testing 
method. For the majority of this study period, susceptibility testing from all blood culture 
isolates was performed using an automated susceptibility testing method called BD 
PhoenixTM. In summer of 2013 through the end of the study period, the clinical 
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microbiological lab began performing E-testing on all MRSA isolates from blood culture. 
Microbiological testing methods are not created equally. BD PhoenixTM tends to 
underestimate the MIC for vancomycin against S. aureus while E-testing tends to be a 
conservative testing method that often overestimates the MIC.68,70 Previously published 
meta-analyses demonstrated adverse clinical outcomes when the vancomycin MIC was 
greater than 1 mg/L by E-test, which may have led to earlier changes in therapy in the 
early and intermediate switch groups.71-73 Clinicians treating patients in the late switch 
group could have been following current IDSA guidelines to let clinical status rather than 
MIC guide therapy change decisions, and thus switched therapy to daptomycin in a later 
time frame.75   
 
Another trend existed between groups and concomitant fungal organisms isolated from 
non-urinary sources. Patients in the late therapy switch group had more non-urinary 
fungal organisms isolated during hospitalization than patients in the early and 
intermediate switch groups. Thirteen isolates were Candida species. One isolate was a 
Cryptococcus neoformans bloodstream infection. Of the Candida isolates, C. albicans 
comprised 23% of fungal isolates. The other 77% were non-albicans species with C. 
glabrata making up 46% of the non-albicans isolates. Invasive candidiasis comprises 
Candida bloodstream infections and other deep-seated tissue infections due to Candida 
and is associated with a 40% mortality rate.117 One of the risk factors for invasive 
candidiasis is broad-spectrum antibiotic use.117 Candida infections represent the 7th most 
common cause of healthcare-associated infections.9,118 Patients in the late therapy switch 
group had significantly higher use of broad-spectrum antibiotic therapy and significantly 
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longer lengths of stay compared to patients in other groups, and thus were pre-disposed to 
more fungal infections. While C. albicans has historically been the dominant Candida 
species, non-albicans species have increased in prevalence. Surveillance data from 40 
hospitals located in the Atlanta and Baltimore metropolitan over a 5-year period 
demonstrated a 64% non-albicans rate with C. glabrata making up the largest proportion 
of those isolates; these numbers are comparable to the prevalence of Candida species in 
this cohort.119 
 
There are several limitations to consider with this study. First, this was a retrospective 
study using data that was already collected for the purposes of diagnosis and treatment of 
disease, not for research purposes. Patients were identified through use of ICD-9 codes 
submitted for administrative purposes and reimbursement. ICD-9 codes used to 
determine enrollment were V09.0 “infection with microorganisms resistant to penicillin”, 
038.11 “S. aureus septicemia”, 038.12 “Methicillin resistant S. aureus septicemia”, 
041.11 “S. aureus infection, site unspecified”, or 041.12 “Methicillin resistant S. aureus 
infection, site unspecified”.96 Previously conducted studies using these ICD-9 codes to 
identify incident S. aureus infections from administrative data have demonstrated low 
sensitivity of 24-65% but high specificity of 99%.120,121 The low sensitivity for 
identifying incident infections may be due to errors in coding including history of S. 
aureus infection or colonization. To increase the specificity in this study, the query of 
encounters with those diagnoses codes were cross-referenced with microbiological data 
specific for S. aureus isolated from blood cultures.  
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The use of microbiological data could have excluded a substantial proportion of patients 
referred to this institution from outside institutions. While transferred patients were not 
excluded explicitly, treatments received at an outside facility may have influenced 
treatment decisions and patient outcomes at this institution. Transferred patients could 
only be included if they had blood cultures growing S. aureus collected at this institution, 
leaving opportunity for misclassification of duration of bacteremia and recurrence of 
infection. 
 
This methodology resulted in a smaller sample size which may limit the external validity 
of these results to other centers. Data herein represents one tertiary care medical center 
that serves as a referral center for a large geographical area comprising central and 
eastern Kentucky. This study would not meet power to detect a meaningful clinical 
difference in treatment failure between early, intermediate, and late therapy switch as 
evidenced by the equal rates of treatment failure across groups. Compared to other 
studies comparing vancomycin and daptomycin, the sample size in this study is 
comparable in size with less than 200 subjects in total.84,85 
 
With respect to assessment of the key response variables, there are a few caveats to 
consider. The primary outcome consisted of all-cause mortality and all-cause 
readmission. Due to the limitations of using administrative coding and administrative 
data to assemble a data set, determining infection-related outcomes would be impractical 
without conducting retrospective chart review. Because the administrative data set 
consisted of one clinical data warehouse from one institution, only readmissions to the 
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studied institution could be ascertained. Additionally, information on outpatient 
completion of antibiotic therapy could not be ascertained without coordinating data with 
third party claims databases. Missing values are a routine challenge when working with 
administrative data and values must be imputed in some cases, which are detailed in 
Appendix C.  
 
This is the first study to directly compare differences in outcomes based on time to 
changing therapy and adds to a body of literature comparing vancomycin to daptomycin 
in clinical practice. Moore and colleagues conducted a study of patients switched from 
vancomycin to daptomycin after a median of 5 days with the rationale for therapy switch 
from vancomycin being lack of improvement or worsening on treatment.84  The primary 
outcome was clinical failure, a composite of 60-day mortality, persistent bacteremia at 7 
days from index culture, and 30-day recurrence. The rate of clinical failure was 17%. 
Murray and colleagues specifically studied patients who were switched to daptomycin 
early in the course of therapy based on vancomycin MIC at a median time of 1.7 days.85 
Their composite clinical failure outcome was defined as 30-day mortality and persistent 
bacteremia. Twenty percent of patients switched to daptomycin experienced clinical 
failure.  
 
Treatment failure rates from the current study were directly compared to treatment failure 
rates from the studies by Moore and Murray (table 5.1). Examining the composite of 60-
day mortality and 30-day recurrence of MRSA BSI the treatment failure rate in the cohort 
from Moore and colleagues was 12%. Examining the composite of 30-day mortality, 30-
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day recurrence of MRSA BSI, and 30-day readmission, the treatment failure rate in the 
cohort from Murray and colleagues was 22%. Analyzing these rates compared to 
treatment failure rates of 18%, 17%, and 18% respectively in the early switch, 
intermediate switch, and late switch groups in the current study, there was no statistically 
significant differences in treatment failure between groups (p=0.62). There were no 
statistically significant differences in mortality or recurrence between the studies. 
Excluding data from the Moore study since readmission was not an outcome of interest, 
there were no differences in readmission between the current study and the Murray 
cohort. There was no difference in treatment failure between the Moore cohort – with a 
median time to switch of 5 days – and the intermediate switch group in the current study 
(12% vs. 17%, p=0.47). There was no difference in treatment failure between the Murray 
cohort – switched at 1.7 days – and the early switch group in the current study (22% vs. 
18%, p=0.66).  
 
Table 5.1: Comparing treatment outcomes between Tennant, Moore, and 
Murray, reported as n (%)84,85 
 Total 
Cohort 
N=337 
Early 
N=49 
Inter-
mediate 
N=76 
Late 
N=68 
Moore 
N=59 
Murray 
N=85 
P-
value 
30-day recurrence 
of S. aureus from 
blood culture 
4 (1%) 
1 
(2%) 
1 (1%) 0 2 (3%) 0 0.23 
60-day mortality 23 (7%) 
3 
(6%) 
6 (8%) 
6 
(9%) 
5 (1%) 3 (1%) 0.64 
90-day 
readmission 
35 
(13%) 
6 
(12%) 
6 (8%) 
7 
(10%) 
-- 
16 
(19%) 
0.20 
Treatment 
failure 
60 
(18%) 
9 
(18%) 
13 (17%) 
12 
(18%) 
7 
(12%) 
19 
(22%) 
0.62 
-- Readmission was not an outcome of interest in the study by Moore and colleagues.84 
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Future study should move away from comparing daptomycin and vancomycin directly 
and should instead focus on identifying which patient factors are risk factors for clinical 
failure, which are associated with clinical success, and how to recognize these as quickly 
as possible to optimize patient outcomes. The key to vancomycin compared to 
daptomycin lies in optimizing use of each agent. Vancomycin exposure and 
subtherapeutic vancomycin levels have been associated with DNS and hVISA 
isolates.90,92 Identifying patients who have previously been exposed to vancomycin or 
who are likely to have suboptimal vancomycin levels may be targets for early initiation of 
daptomycin. Further clarifying the ideal time to therapy switch and the ideal duration of 
each vancomycin and daptomycin are other questions to answer.  
 
Paramount to patient success is optimizing management of SAB independent of 
antimicrobial therapy. Ensuring clearance of bacteremia is vital as persistent 
staphylococcal bacteremia is associated with 10-times higher risk of relapse and 2.6-
times higher odds of in-hospital mortality.75,122 Patients with relapsed SAB are likely to 
be re-exposed to vancomycin, and multiple exposures should be minimized to reduce the 
risk of decreased susceptibility vancomycin and daptomycin. A study by Carugati and the 
International Collaboration on Endocarditis demonstrated that in patients with MRSA IE, 
patients definitively treated with daptomycin cleared bacteremia faster than patients 
treated with standard-of-care regimens, including vancomycin (1.0 day vs. 5.0 days, 
[p<0.01]).123 This supports switching to daptomycin in persistent bacteremia, though 
ensuring optimal vancomycin levels is also important to ensuring expedient clearance of 
blood cultures.41,124,125 In a case-control study comparing patients with persistent SAB to 
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patients with resolving bacteremia, initial vancomycin trough less than 15 mg/L was 
associated with 4-times higher odds of having persistent SAB (OR, 4.25 [95% CI, 1.51-
11.96]).125 Utilizing vancomycin and daptomycin in combination regimens with a beta-
lactam for persistent bacteremia is a present topic of several studies.29,88 As previously 
discussed, source control to remove nidi of infection is the ultimate cure for SAB.106,107 
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CHAPTER SIX: CONCLUSION 
 
This is the first study to directly compared patients switched from vancomycin to 
daptomycin for treatment of S. aureus bacteremia. Patients were stratified into groups 
based on early therapy switch (within 1-3 days of starting treatment), intermediate 
therapy switch (within 4-7 days of starting treatment), or late therapy switch (after 7 days 
of treatment). This study did not detect a difference in treatment failure rates, defined as 
30-day recurrence of S. aureus from blood culture, 60-day all-cause mortality after first 
positive blood culture, or 90-day all-cause readmission after first positive blood culture. 
Length of stay was positively associated with treatment success while time to positive 
cultures was negatively associated with treatment success. 
 
Future research directions should focus on optimizing use of vancomycin and 
daptomycin and medical management of SAB. Previous vancomycin exposure and 
suboptimal vancomycin concentrations are associated with decreased vancomycin and 
daptomycin susceptibility. Future studies can identify patients at risk for multiple 
vancomycin exposures. Which patient factors are risk factors for clinical failure, which 
are associated with clinical success, and how to recognize these as quickly as possible to 
optimize patient outcomes are questions that still need to be answered. 
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APPENDIX A 
 
Clinical Data Points Queried from University of Kentucky HealthCare Enterprise Data 
Trust 
 
Clinical Data Point 
ICD 9 Code 
(if applicable) 
Demographics  
Age at admission  
Gender  
Race  
Admission height  
Admission weight  
Body mass index  
Inpatient location history  
Clinical History  
Charlson comorbidity index  
History of intravenous drug abuse  
Drug dependence 304.xx 
Other, mixed, or unspecific drug abuse, unspecified 305.90 
Presence of cardiac prosthesis  
Heart valve replaced by other means V43.3 
Automatic implantable cardiac defibrillator in situ V45.02 
Cardiac pacemaker in situ V45.01 
Osteoarticular source of infection  
Osteomyelitis periostitis and other infections involving bone 730.xx 
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Infection and inflammatory reaction due to internal joint 
prosthesis 
996.66 
Infection and inflammatory reaction due to other internal 
orthopedic device, implant, or graft 
996.67 
Abscess of spinal cord 324.1 
Other sources of infection  
Bloodstream infection due to central venous catheter 999.32 
Infection and inflammatory reaction due to cardiac device, 
implant, or graft 
996.61 
Infection and inflammatory reaction due to nervous system 
device, implant, or graft 
996.63 
Infection and inflammatory reaction due to indwelling urinary 
catheter device, implant, or graft 
996.64 
Infection and inflammatory reaction due to other genitourinary 
device, implant, or graft 
996.65 
Infection and inflammatory reaction due to peritoneal dialysis 
device, implant, or graft  
996.68 
Infection and inflammatory reaction due to other internal 
prosthetic device, implant, or graft 
 
 
996.69 
Medication Information 
Daptomycin dose, administration date and time, order 
discontinuation date and time 
Vancomycin dose, administration date and time, order 
discontinuation date and time 
 
Dose, administration date and time, order discontinuation date and 
time for other anti-infective agents 
 
Aminoglycosides  
Antifungals  
Antituberculosis agents  
Antiviral agents  
Carbapenems  
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Cephalosporins  
Glycylcyclines  
Leprostatics  
Lincomycin derivatives  
Macrolide derivatives  
Miscellaneous antibiotics (aztreonam, colistimethate, 
dalfopristin-quinupristin, linezolid, metronidazole, polymyxin 
B) 
 
Penicillins  
Quinolones  
Sulfamethoxazole/trimethoprim  
Microbiology Results  
Positive blood cultures  
Daptomycin susceptibility  
Oxacillin susceptibility  
Vancomycin susceptibility  
Susceptibility testing method  
Laboratory Values  
Creatine kinase  
Serum creatinine  
Vancomycin trough level  
Clinical Outcomes  
Echocardiogram performed  
Infectious diseases service consultation  
Cardiac source control procedures  
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Operations on valves and septa of heart 35.xx 
Other operations on heart and pericardium 37.xx 
Skin/soft tissue source control procedures See Appendix 
B 
Osteoarticular source control procedures See Appendix 
B 
Hospital length of stay  
Discharge status  
Time to readmission  
Date of death  
Safety Outcomes  
Rhabdomyolysis 728.88 
Intestinal infection due to Clostridium difficile 008.45 
ICD 9 - International Classification of Diseases, 9th Revision 
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APPENDIX B 
Current Procedural Terminology (CPT) Codes for Source Control Procedures Queried 
from University of Kentucky HealthCare Enterprise Data Trust 
 
Procedure CPT Code Range 
Incision and drainage procedures on the skin, subcutaneous, 
and accessory structures 
10040-10180 
Debridement procedures on the skin 11000-11047 
Biopsy procedures on the skin 11100-11101 
Removal of skin tags procedures 11200-11201 
Excision-benign lesions procedures on the skin 11400-11471 
Excision-malignant lesions procedures on the skin 11600-11646 
Skin replacement surgery 1500-15278 
Pressure ulcers (decubitus ulcers) procedures 15920-15999 
Local treatment procedures for burns 1600-16036 
General introduction or removal procedures on the 
musculoskeletal system 
20500-20697 
Excision procedures on the neck (soft tissues) and thorax 21550-21632 
Repair, revision, and/or reconstruction procedures on the 
neck (soft tissues) and thorax 
21685-21750 
Fracture and/or dislocation procedures on the neck (soft 
tissues) and thorax 
21805-21825 
Excision procedures on the spine (vertebral column) 22100-22116 
Osteotomy procedures on the spine (vertebral column) 22206-22226 
Fracture and/or dislocation procedures on the spine 
(vertebral column) 
22305-22328 
Arthrodesis procedures of the spine (vertebral column) 22532-22819 
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Spinal instrumentation procedures on the spine (vertebral 
column) 
22840-22865 
Incision procedures on the shoulder 23000-23044 
Excision procedures on the shoulder 23065-23229 
Introduction or removal procedures of the shoulder 23330-23350 
Repair, revision, and/or reconstruction procedures on the 
shoulder 
23395-23491 
Fracture and/or dislocation procedures on the shoulder 23500-23680 
Arthrodesis procedures on the shoulder 23800-23802 
Amputation procedures on the shoulder 23900-23921 
Other procedures on the shoulder 23929-23929 
Incision procedures on the humerus (upper arm) and elbow 23930-24006 
Excision procedures on the humerus (upper arm) and elbow 24065-24115 
Introduction or removal procedures on the humerus (upper 
arm) and elbow 
24160-24220 
Repair, revision, and/or reconstruction procedures on the 
humerus (upper arm) and elbow 
24300-24498 
Fracture and/or dislocation procedures on the humerus 
(upper arm) and elbow 
24500-24685 
Arthrodesis procedures on the humerus (upper arm) and 
elbow 
24800-24802 
Amputation procedures on the humerus (upper arm) and 
elbow 
24900-24940 
Incision procedures on the forearm and wrist 25000-25040 
Excision procedures on the forearm and wrist 25065-25240 
Introduction or removal procedures on the forearm and wrist 25246-25259 
Repair, revision, and/or reconstruction procedures on the 
forearm and wrist 
25260-25492 
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Fracture and/or dislocation procedures on the forearm and 
wrist 
25500-25695 
Arthrodesis procedures on the forearm and wrist 25800-25830 
Amputation procedures on the forearm and wrist 25900-25931 
Incision procedures on the hand and fingers 26010-26080 
Excision procedures on the hand and fingers 26100-26262 
Introduction and removal procedures on the hand and 
fingers 
26320-26320 
Repair, revision, and/or reconstruction procedures on the 
hand and fingers 
26340-26596 
Fracture and/or dislocation procedures on the hand and 
fingers 
26600-26785 
Amputation procedures on the hand and fingers 26820-26863 
Incision procedures on the pelvis and hip joint 26990-27036 
Excision Incision procedures on the pelvis and hip joint 27040-27080 
Introduction or removal Incision procedures on the pelvis 
and hip joint 
27086-27096 
Repair, revision, and/or reconstruction Incision procedures 
on the pelvis and hip joint 
27097-27187 
Fracture and/or dislocation Incision procedures on the pelvis 
and hip joint 
27193-27269 
Manipulation procedures on the pelvis and hip joint 27275-27275 
Arthrodesis procedures on the pelvis and hip joint 27279-27286 
Amputation procedures on the pelvis and hip joint 27290-27295 
Incision procedures on the femur (thigh region) and knee 
joint 
27301-27310 
Excision procedures on the femur (thigh region) and knee 
joint 
27323-27365 
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Repair, revision, and/or reconstruction procedures on the 
femur (thigh region) and knee joint 
27380-27499 
Fracture and/or dislocation procedures on the femur (thigh 
region) and knee joint 
27500-27566 
Manipulation procedures on the femur (thigh region) and 
knee joint 
27570-27570 
Amputation procedures on the femur (thigh region) and 
knee joint 
27590-27598 
Incision procedure on the leg (tibia and fibula) and ankle 
joint 
27600-27612 
Excision procedure on the leg (tibia and fibula) and ankle 
joint 
27613-27647 
  
Repair, revision, and/or reconstruction procedure on the leg 
(tibia and fibula) and ankle joint 
27650-27745 
Arthrodesis procedure on the leg (tibia and fibula) and ankle 
joint 
27870-27871 
Amputation procedure on the leg (tibia and fibula) and ankle 
joint 
27880-27889 
Incision procedures on the foot and toes 28001-28035 
Excision procedures on the foot and toes 28039-28175 
Removal of foreign body procedures on the foot and toes 28190-28193 
Repair, revision, and/or reconstruction procedures on the 
foot and toes 
28200-28360 
Fracture and/or dislocation procedures on the foot and toes 28400-28675 
Arthrodesis procedures on the foot and toes 28705-28760 
Amputation procedures on the foot and toes 28800-28825 
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APPENDIX C 
Variable Definitions and Characteristics 
 
Study Variable Dataset Variable Definition 
Outcomes Variables 
Treatment failure 
(primary efficacy 
outcome) 
mort60 + readmit90 + 
recur30 
A composite outcome where if 
any of those conditions were 
met, then considered a 
treatment failure and fail=1 
60-day mortality cx_to_death, cul1, 
DEATH_DT 
Determined by the number of 
days between first positive 
blood culture collection and 
date of death. If missing, then 
DEATH_DT=999. If <60 then 
mort60=1 
90-day all-cause 
readmission 
DAYS_TO_READMIT Days between encounters. If 
missing, then 
DAYS_TO_READMIT=999. 
If <90 then readmit90=1 
30-day recurrence of S. 
aureus from blood 
culture 
cul1, cul2 If days between collection of 
1st positive culture and 2nd 
positive culture after initial 
clearance <30 then recur30=1  
Clostridium difficile 
infection (safety 
outcome) 
C_DIFF Diagnosis based on ICD-9 
code, see Appendix A 
Rhabdomyolysis (safety 
outcome) 
RHABDOMYOLYSIS, 
HighCK, 
Diagnosis based on ICD-9 
code, see Appendix A, creatine 
kinase(CK) value >1500 
Nephrotoxicity (safety 
outcome) 
risk_cr + risk_crcl + inj_cr 
+ inj_crcl + fail_cr + 
fail_crcl 
A composite outcome where if 
RIFLE criteria were met by 
serum creatinine or creatinine 
clearance definitions, then 
nephrotoxicity=1 
Study Covariates 
Gender GENDR_CD Derived gender available in 
EDT 
Race RACE_CD_DES Derived race available in EDT 
Age AGE Derived age at time of 
encounter available in EDT 
Charlson comorbidity 
index 
COMORBIDITY_SCORE Derived severity of illness 
score available in EDT 
Admitted to intensive 
care unit 
ADM2ICU Derived from admission 
location available in EDT 
History of intravenous 
drug use 
IV_DRUG Diagnosis based on ICD-9 
code, see Appendix A 
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Cardiac prosthesis CARDIAC_PROSTHESI
S 
Diagnosis based on ICD-9 
code, see Appendix A 
Time to positive culture cul1, ADMT_DT Days between admission date 
and first positive blood culture  
Time to clear blood 
cultures 
cul1, cul2 Days between first positive 
blood culture and last positive 
blood culture 
Methicillin-resistant S. 
aureus 
OXA_SUSC, MRSA If OXA_SUSC=0 then 
MRSA=1 
Vancomycin minimum 
inhibitory concentration 
(MIC) 
VANMIC Derived from vancomycin 
MIC or susceptibility available 
in EDT. If only reported as 
susceptible, then VANMIC=1 
Daptomycin MIC DAP_S, DAPTMIC Derived from daptomycin MIC 
or susceptibility available in 
EDT. If only reported as 
susceptible, then 
DAPTMIC=1. If only reported 
as non-susceptible, then 
DAPTMIC=1.5 
E-test performed MIC_Method Derived from susceptibility 
testing method available in 
EDT 
Length of stay LOS Derived length of stay 
available in EDT 
Source control achieved bjsrccntrl, cardsrccntrl, 
linesrccntrl, 
source_control 
Based on CPT codes, see 
Appendix B 
Duration of therapy D_DOT + V_DOT Sum of days of therapy of 
daptomycin and day of therapy 
of vancomycin 
Polymicrobial 
bloodstream infection 
polymicro_BSI, 
gram_neg_BSI, 
gram_pos_BSI, 
fungal_BSI 
Indicates if another organism 
grew in the same blood culture 
as a S. aureus isolate 
Other infectious 
organisms 
other_orgs, 
other_gram_neg, 
other_gram_pos,  
Indicates if another organism 
grew from subsequent blood 
cultures or other tissue samples 
Fungal organisms other_fungal, 
non_urine_fungal, source, 
species 
Indicates if a fungus grew from 
subsequent blood cultures or 
other tissue samples. Describes 
site of fungal growth and 
fungal species identified. 
Fungi was determined to be a 
urinary source if >100,000 
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colony forming units of fungal 
species grew from urine 
culture with no concomitant 
positive blood or non-
pulmonary tissue sources 
Ceftaroline CEFTRLN Indicates ceftaroline was 
administered during the 
encounter 
Gentamicin GENTMC Indicates gentamicin was 
administered during the 
encounter 
Rifampin RIFMPN Indicates rifampin was 
administered during the 
encounter 
Trimethoprim-
Sulfamethoxazole 
SMXTMP Indicates 
trimethoprim/sulfamethoxazol
e was administered during the 
encounter 
Cefepime CEFPM Indicates cefepime was 
administered during the 
encounter 
Cefazolin CEFZLN Indicates cefazolin was 
administered during the 
encounter 
Meropenem MERPNM Indicates meropenem was 
administered during the 
encounter 
Nafcillin NAFCLLN Indicates nafcillin was 
administered during the 
encounter 
Piperacillin/Tazobacta
m 
PIPTZB Indicates 
piperacillin/tazobactam was 
administered during the 
encounter 
Tobramycin or 
Amikacin 
Other_AG Indicates tobramycin or 
amikacin was administered 
during the encounter 
Amphotericin 
formulation 
AMPHBLIP + ABLC Indicates an amphotericin B 
formulation was administered 
during the encounter 
Daptomycin dose dapto_mg, INIT_WT First daptomycin dose 
administered divided by initial 
weight. If INIT_WT missing, 
then imputed as standard 70kg 
Vancomycin trough firstvanc_lvl2 First vancomycin trough serum 
concentration collected 
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Baseline glomerular 
filtration rate (GFR) 
AGE, FIRST_CRVAL First GFR calculated using a 
modified Cockcroft-Gault 
equation 
Baseline creatine kinase 
(CK) 
baselineCK Derived from first CK value 
available in EDT 
EDT=Enterprise Data Trust 
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APPENDIX D 
Full Logistic Regression Model for Treatment Success Adjusting for Significant 
Covariates 
 
 Odds Ratio 
Estimate 
95% 
Confidence Interval 
P-
value 
Group 1.043 0.581 1.873 0.8882 
Time to positive culture, days 0.967 0.929 1.007 0.1081 
Vancomycin MIC, mg/L 1.013 0.293 3.498 0.9839 
Length of stay, days 1.023 0.994 1.053 0.1276 
Ceftaroline 1.316 0.418 4.149 0.6389 
Sulfamethoxazole/Trimethoprim 0.402 0.085 1.892 0.2487 
Piperacillin/Tazobactam 1.112 0.468 2.642 0.8099 
Tobramycin or Amikacin 2.219 0.514 9.572 0.2853 
Amphotericin 0.385 0.074 1.999 0.2562 
IV Drug Use 2.425 0.493 11.939 0.2761 
Other Infectious Organisms 0.342 0.091 1.279 0.1108 
Gram Negative Organisms 3.176 0.833 12.103 0.0905 
Gram Positive Organisms 0.684 0.182 2.569 0.5742 
Fungal Organisms from Non-Urinary 
Source 
1.213 0.205 7.173 0.8311 
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